Drug Combination Details
| General Information of the Combination (ID: C66955) | |||||
|---|---|---|---|---|---|
| Name | Ginsenoside Rg3 NP Info | + | Cyclophosphamide Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
|
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | PCNA | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | PECAM1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Female athymic mice were transplanted with 0.2 mL (1*107 /mL) cell suspension of SKOV-3 cells at the subcutaneous of armpit in right anterior superior limbs. | |||||
| Experimental
Result(s) |
Ginsenoside Rg3 and CTX combination reinforced the antitumour effect each other and improved the living quality and survival time of mice with tumour. | |||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vivo Model | Lewis lung carcinoma (1*106/0.1 mL) was inoculated subcutaneously in the right flank of each C57/BL6 mouse. | |||||
| Experimental
Result(s) |
Continuous low-dose regimen of CTX increases the efficacy of targeting the tumor microvasculature, which produces therapeutic activity with decreased toxicity. | |||||
